187 related articles for article (PubMed ID: 33065408)
21. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study.
Cella CA; Di Minno G; Carlomagno C; Arcopinto M; Cerbone AM; Matano E; Tufano A; Lordick F; De Simone B; Muehlberg KS; Bruzzese D; Attademo L; Arturo C; Sodano M; Moretto R; La Fata E; De Placido S
Oncologist; 2017 May; 22(5):601-608. PubMed ID: 28424324
[TBL] [Abstract][Full Text] [Related]
22. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
[TBL] [Abstract][Full Text] [Related]
23. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.
Muñoz A; Ay C; Grilz E; López S; Font C; Pachón V; Castellón V; Martínez-Marín V; Salgado M; Martínez E; Calzas J; Ortega L; Rupérez A; Salas E; Pabinger I; Soria JM
J Clin Oncol; 2023 Jun; 41(16):2911-2925. PubMed ID: 36730884
[TBL] [Abstract][Full Text] [Related]
24. The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study.
Overvad TF; Skjøth F; Piazza G; Noble S; Ording AG; Larsen TB; Nielsen PB
J Thromb Haemost; 2022 Dec; 20(12):2921-2929. PubMed ID: 36112135
[TBL] [Abstract][Full Text] [Related]
25. Influence of type 2 diabetes mellitus on Khorana venous thromboembolism risk in colorectal cancer patients.
Wang R; Liu R; Zhao L; Xu D; Hu L
Rev Esp Enferm Dig; 2017 Jul; 109(7):503-509. PubMed ID: 28593781
[TBL] [Abstract][Full Text] [Related]
26. PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL).
Santi RM; Ceccarelli M; Catania G; Monagheddu C; Evangelista A; Bernocco E; Monaco F; Federico M; Vitolo U; Cortelazzo S; Cabras MG; Spina M; Baldini L; Boccomini C; Chiappella A; Bari A; Luminari S; Calabrese M; Levis A; Visco C; Contino L; Ciccone G; Ladetto M
Thromb Res; 2016 Apr; 140 Suppl 1():S177. PubMed ID: 27161692
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma.
Sanfilippo KM; Carson KR; Wang TF; Luo S; Edwin N; Kuderer N; Keller JM; Gage BF
Res Pract Thromb Haemost; 2022 Jan; 6(1):e12634. PubMed ID: 35028491
[TBL] [Abstract][Full Text] [Related]
28. Venous thromboembolism in cancer patients.
Deng A; Galanis T; Graham MG
Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer.
Guman NAM; van Geffen RJ; Mulder FI; van Haaps TF; Hovsepjan V; Labots M; Cirkel GA; Y F L de Vos F; Ten Tije AJ; Beerepoot LV; Tjan-Heijnen VCG; van Laarhoven HWM; Hamberg P; Vulink AJE; Los M; Zwinderman AH; Ferwerda B; Lolkema MPJK; Steeghs N; Büller HR; Kamphuisen PW; van Es N
J Thromb Haemost; 2021 Dec; 19(12):2974-2983. PubMed ID: 34409743
[TBL] [Abstract][Full Text] [Related]
30. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer.
Mansfield AS; Tafur AJ; Wang CE; Kourelis TV; Wysokinska EM; Yang P
J Thromb Haemost; 2016 Sep; 14(9):1773-8. PubMed ID: 27273134
[TBL] [Abstract][Full Text] [Related]
31. Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer.
Piver RN; Wagner VM; Levine MD; Backes FJ; Chambers LJ; Cohn DE; Copeland LJ; Cosgrove CM; Nagel CI; O'Malley DM; Bixel KL
Gynecol Oncol Rep; 2023 Apr; 46():101156. PubMed ID: 36910448
[TBL] [Abstract][Full Text] [Related]
32. The Application of Current Proposed Venous Thromboembolism Risk Assessment Model for Ambulatory Patients With Cancer.
Abdel-Razeq H; Mansour A; Saadeh SS; Abu-Nasser M; Makoseh M; Salam M; Abufara A; Ismael Y; Ibrahim A; Khirfan G; Ibrahim M
Clin Appl Thromb Hemost; 2018 Apr; 24(3):429-433. PubMed ID: 28183196
[TBL] [Abstract][Full Text] [Related]
33. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
Thaler J; Ay C; Pabinger I
Thromb Haemost; 2012 Dec; 108(6):1042-8. PubMed ID: 22836491
[TBL] [Abstract][Full Text] [Related]
34. High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score.
Castellón Rubio VE; Segura PP; Muñoz A; Farré AL; Ruiz LC; Lorente JA
Thromb Res; 2020 Dec; 196():349-354. PubMed ID: 32977135
[TBL] [Abstract][Full Text] [Related]
35. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis.
Mulder FI; Candeloro M; Kamphuisen PW; Di Nisio M; Bossuyt PM; Guman N; Smit K; Büller HR; van Es N;
Haematologica; 2019 Jun; 104(6):1277-1287. PubMed ID: 30606788
[TBL] [Abstract][Full Text] [Related]
36. Estimating Venous Thromboembolism Risk in Metastatic Colorectal Cancer Inpatients: Validation of Existing Risk Scores and Development of New Risk Scores.
Qin L; Liang Z; Xie J; Li X
Clin Appl Thromb Hemost; 2023; 29():10760296231196859. PubMed ID: 37691565
[TBL] [Abstract][Full Text] [Related]
37. COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.
Abdel-Razeq H; Sharaf B; Al-Jaghbeer MJ; Abu-Fares H; Bater R; Shaer MA; Abu-Jaish H; Laban DA; Salamah O; Tamimi F; Ashouri K; Salameh T; Zughul R; Alhalaseh Y
J Thromb Thrombolysis; 2023 Oct; 56(3):447-453. PubMed ID: 37430158
[TBL] [Abstract][Full Text] [Related]
38. Models for predicting venous thromboembolism in ambulatory patients with lung cancer: A systematic review and meta-analysis.
Yan AR; Samarawickrema I; Naunton M; Peterson GM; Yip D; Newman P; Mortazavi R
Thromb Res; 2024 Feb; 234():120-133. PubMed ID: 38215613
[TBL] [Abstract][Full Text] [Related]
39. Retrospective Cohort Study of Venous Thromboembolism Rates in Ambulatory Cancer Patients: Association With Khorana Score and Other Risk Factors.
Austin K; George J; Robinson EJ; Scully M; Thomas MR
J Hematol; 2019 Mar; 8(1):17-25. PubMed ID: 32300436
[TBL] [Abstract][Full Text] [Related]
40. Development and Validation of a Modified Khorana Score for Predicting Venous Thromboembolism in Newly Diagnosed Stage IV Lung Cancer.
Qin Y; Liang X; Wu H; Sun X; Yan S; Wang N; Yuan M; Wang Q; Wu D
Angiology; 2023 Nov; ():33197231213197. PubMed ID: 37924222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
